2,4,6-TMPEA-NBOMe
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2,4,6-TMPEA-NBOMe, also known as ψ-2C-O-NBOMe or 26O-NBOMe as well as N-(2-methoxybenzyl)-2,4,6-trimethoxyphenethylamine, is a psychedelic drug of the phenethylamine, ψ-PEA, and N-benzylphenethylamine (NBOMe) families.[1][2][3][4][5] It is the NBOMe derivative of ψ-2C-O (2,4,6-TMPEA).[5] The drug is said to produce psychedelic effects such as visuals.[1][2] It has been found to act as a potent serotonin 5-HT2A receptor partial agonist, with an EC50 of 1.7 nM and an Emax of 49%.[3][4] 2,4,6-TMPEA-NBOMe was first described in the scientific literature in 2009.[3][4] Subsequently, it was encountered as a novel designer drug in Russia in 2015.[5][1][2] The drug is a controlled substance in Canada under phenethylamine blanket-ban language.[6]
- None
| Clinical data | |
|---|---|
| Other names | ψ-2C-O-NBOMe; 26O-NBOMe; NBOMe-TMPEA-6; N-(2-Methoxybenzyl)-2,4,6-trimethoxyphenethylamine |
| Routes of administration | Oral, intranasal[1][2] |
| Drug class | Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C19H25NO4 |
| Molar mass | 331.412 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- 25-NB (psychedelics)
- NBOMe-mescaline (3,4,5-TMPEA-NBOMe)
- 25O-NBOMe (2,4,5-TMPEA-NBOMe)